India, July 14 -- Shares of NextCure, Inc. (NXTC) skyrocketed more than 200% on Tuesday after the company agreed to merge with privately held Avere Therapeutics in an all-stock deal. The company also announced a concurrent $320 million private financing to advance Avere's lead inflammatory disease therapy.
The stock is currently trading at $6.90, up $4.72, or 216.69%, after opening at $9.26. It previously closed at $2.18 and has traded in a 52-week range of $1.55 to $15.74.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....